^
Association details:
| Biomarker: | EPAS1 G323E |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Welireg (belzutifan) (HIF-2α inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MP04-12: Pharmacological inhibition of the molecular chaperone Hsp70 overcomes Belzutifan resistance in ccRCC
Published date:
03/31/2023
Excerpt:
Utilizing previously characterized Belzutifan resistant HIF2a-S304M and -G323E mutants we demonstrated that treating ccRCC cells with Hsp70 inhibitor JG-98 leads to mutant-HIF2a degradation, therefore overcoming Belzutifan resistance….treatment with an Hsp70 inhibitor could potentially be used in the clinic to overcome resistance to Belzutifan in patients with VHL disease and ccRCC.
Secondary therapy:
HSP70 inhibitor
